Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.95 +0.45 (+2.57%)

Delayed Quote Updated: 2:50 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

36 37 Next >

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm

June 16, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm

June 16, 2025

Via TheNewswire.com

Topics Fraud

Monday's session: top gainers and losers ↗

June 16, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June ↗

June 16, 2025

Via Benzinga

Topics Stocks

Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (28 Ratings) ↗

June 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 16, 2025

Via Benzinga

What the Options Market Tells Us About Sarepta Therapeutics ↗

June 16, 2025

Via Benzinga

Why Sarepta Therapeutics (SRPT) Stock Is Down Today

June 16, 2025

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy,....

Via StockStory

Top movers in Monday's session ↗

June 16, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Sarepta Therapeutics Stock Alert: Investors of Sarepta May Have Legal Claims and Are Encouraged to Contact Kehoe Law Firm, P.C. - SRPT

June 16, 2025

Via ACCESS Newswire

These stocks are gapping in today's session ↗

June 16, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

US Stocks Higher; Dow Jumps Over 400 Points ↗

June 16, 2025

Via Benzinga

Topics Stocks

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

June 16, 2025

Via Benzinga

Sarepta Therapeutics Stock Plunges On Multiple Downgrades Following Patient Death: Retail Questions ‘Crazy’ Price Targets ↗

June 16, 2025

Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion.

Via Stocktwits

Topics Death

Sarepta Therapeutics Plummets 43% After A Second Gene Therapy Recipient Dies ↗

June 16, 2025

The company is working with an independent group to determine if there's a better immunosuppressive regimen.

Via Investor's Business Daily

Topics Death Government

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

Monday's pre-market session: top gainers and losers ↗

June 16, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

Dow Futures Edge Up As Israel-Iran Conflict Spares Oil Capacity: US Steel, Tesla, Victoria’s Secret, Sarepta Among Stocks To Watch ↗

June 16, 2025

While Dow Jones futures gained 0.41% at the time of writing, the S&P 500 futures rose 0.48%.

Via Stocktwits

Topics ETFs Government Stocks

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy ↗

June 16, 2025

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Via Benzinga

Topics Death

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

June 16, 2025

Via Benzinga

Sarepta Pauses DMD Gene Therapy Trial After Second Death; Retail Traders Brush Off Risk ↗

June 15, 2025

BMO Capital downgraded the stock, warning of rising regulatory uncertainty and potential revenue impact.

Via Stocktwits

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

June 15, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer ↗

June 05, 2025

RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.

Via Benzinga

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

June 04, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

1 Value Stock on Our Buy List and 2 to Approach with Caution

June 02, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar

May 30, 2025

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm

May 29, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm

May 29, 2025

Via TheNewswire.com

Topics Fraud

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm

May 22, 2025

Via TheNewswire.com

Topics Fraud

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.